Mice that received intracranial injection of CCR2+HSCs demonstrated increased IFN-γ secretion by peripheral T cells in response to tumor antigens, suggesting that these T cells were cross-primed, presumably by the cells derived from the CCR2+HSCs that differentiated into antigen presenting cells in the tumor and extravasated into the draining lymph node (Fig. 5b). The gene discussed is CCR2; the disease is neoplasm.